000294751 001__ 294751
000294751 005__ 20250520092806.0
000294751 0247_ $$2doi$$a10.1007/s00330-024-11191-8
000294751 0247_ $$2pmid$$apmid:39604650
000294751 0247_ $$2ISSN$$a0938-7994
000294751 0247_ $$2ISSN$$a1432-1084
000294751 0247_ $$2ISSN$$a1613-3749
000294751 0247_ $$2ISSN$$a1613-3757
000294751 0247_ $$2ISSN$$a(ISSN
000294751 0247_ $$2ISSN$$aDES
000294751 0247_ $$2ISSN$$aSUPPLEMENTS)
000294751 037__ $$aDKFZ-2024-02466
000294751 041__ $$aEnglish
000294751 082__ $$a610
000294751 1001_ $$0P:(DE-He78)2af28acfaad8f466abb166306f9597bd$$aNeelsen, Christian Jan Oliver$$b0$$eFirst author$$udkfz
000294751 245__ $$aSplenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.
000294751 260__ $$aHeidelberg$$bSpringer$$c2025
000294751 3367_ $$2DRIVER$$aarticle
000294751 3367_ $$2DataCite$$aOutput Types/Journal article
000294751 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747726040_3491
000294751 3367_ $$2BibTeX$$aARTICLE
000294751 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294751 3367_ $$00$$2EndNote$$aJournal Article
000294751 500__ $$a#EA:E010# / 2025 Jun;35(6):3576-3586
000294751 520__ $$aThis study aims to evaluate correlations between spleen signal changes in different MRI sequences and bone marrow plasma cell infiltration as potential indicator of disease burden in multiple myeloma (MM) patients.We retrospectively analyzed 45 patients with newly diagnosed MM that underwent whole-body MRI with axial DWI at b-values 50 (b50) and 800 (b800), and coronal T1 and T2 fast spin-echo (T2-TSE) imaging. A subcohort of 39 patients had concomitant [18F]FDG PET/CT. The spleen was segmented in all MRI sequences and signal intensities were normalized. MR signal intensities and ADC values were correlated with bone marrow plasma cell infiltration from biopsy, laboratory markers (Beta 2-microglobulin, M-Protein, Red blood count (RBC), Hemoglobin, Hematocrit, Total protein, Creatinine), clinical data (ISS stages, high-risk chromosomal aberrations), and standardized uptake value (SUV) in the spleen as well as spleen-to-liver and spleen-to-blood pool SUV ratios on [18F]FDG PET-CT.Bone marrow plasma cell infiltration was negatively correlated with (normalized) mean splenic signal intensity on DWI-b50, DWI-b800, and T2-TSE images (r = -0.64, p < 0.001, r = -0.58, p < 0.001, and r = -0.66, p < 0.001, respectively) while there was no correlation with the apparent diffusion coefficient or spleen size (p = 0.52). In the subgroup analysis of 39 patients with concomitant [18F]FDG PET-CT, there was no correlation of normalized splenic [18F]FDG uptake either with MR spleen signal (for T2 p = 0.64) or with bone marrow plasma cell infiltration (p = 0.37).Our findings reveal a significant association between spleen signal intensity especially on normalized T2-weighted images and tumor burden.Question What changes occur in spleen signal on MRI as tumor load marker changes in multiple myeloma (MM)? Findings Spleen signal intensity, particularly on T2-weighted MRI, negatively correlates with bone marrow plasma cell infiltration and laboratory markers of tumor burden. Clinical relevance Standardized quantification of splenic T2 signal is proposed as a new marker for MM disease burden.
000294751 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000294751 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294751 650_7 $$2Other$$aMultiparametric magnetic resonance imaging
000294751 650_7 $$2Other$$aMultiple myeloma
000294751 650_7 $$2Other$$aNeoplasm staging
000294751 650_7 $$2Other$$aPositron emission tomography computed tomography
000294751 650_7 $$2Other$$aSpleen
000294751 7001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b1$$udkfz
000294751 7001_ $$aJohn, Lukas$$b2
000294751 7001_ $$0P:(DE-He78)64313331bb3bdc0902ff88697f402c92$$aNeher, Peter$$b3$$udkfz
000294751 7001_ $$aMai, Elias$$b4
000294751 7001_ $$0P:(DE-He78)cf4656ab05919cc784af4e9812f5a9fa$$aGrözinger, Martin$$b5$$udkfz
000294751 7001_ $$0P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aPaech, Daniel$$b6$$udkfz
000294751 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b7$$udkfz
000294751 7001_ $$0P:(DE-He78)ea7f20e71e3cb1a864c23f2f09f0b0b9$$aKurz, Felix T$$b8$$udkfz
000294751 7001_ $$aSauer, Sandra$$b9
000294751 7001_ $$aRaab, Marc S$$b10
000294751 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b11$$udkfz
000294751 7001_ $$0P:(DE-He78)e7c860fe438c12cbe5f071b3f86d5738$$aWennmann, Markus$$b12$$udkfz
000294751 7001_ $$aWeinhold, Niels$$b13
000294751 773__ $$0PERI:(DE-600)1472718-3$$a10.1007/s00330-024-11191-8$$n6$$p3576-3586$$tEuropean radiology$$v35$$x0938-7994$$y2025
000294751 909CO $$ooai:inrepo02.dkfz.de:294751$$pVDB
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2af28acfaad8f466abb166306f9597bd$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)64313331bb3bdc0902ff88697f402c92$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cf4656ab05919cc784af4e9812f5a9fa$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea7f20e71e3cb1a864c23f2f09f0b0b9$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000294751 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e7c860fe438c12cbe5f071b3f86d5738$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000294751 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000294751 9141_ $$y2024
000294751 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-19$$wger
000294751 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-19$$wger
000294751 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR RADIOL : 2022$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000294751 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR RADIOL : 2022$$d2023-08-19
000294751 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000294751 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x1
000294751 9201_ $$0I:(DE-He78)E230-20160331$$kE230$$lE230 Medizinische Bildverarbeitung$$x2
000294751 9200_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000294751 980__ $$ajournal
000294751 980__ $$aVDB
000294751 980__ $$aI:(DE-He78)E010-20160331
000294751 980__ $$aI:(DE-He78)E060-20160331
000294751 980__ $$aI:(DE-He78)E230-20160331
000294751 980__ $$aUNRESTRICTED